

Special Issue

Combination Immunotherapy for Cancer Treatment—2nd Edition

Message from the Guest Editor

This Special Issue will be dedicated to exploring the fascinating field of combination immunotherapy and its potential to revolutionize cancer treatment. In recent years, immunotherapy has emerged as an exciting approach in the fight against cancer, harnessing the power of the immune system to target and destroy cancer cells. However, single-agent immunotherapy has shown limitations in achieving complete and durable responses in all patients. That is where combination immunotherapy comes into play. By combining different immunotherapeutic agents, such as immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell transfer, researchers and clinicians aim to enhance the effectiveness of treatment and overcome resistance mechanisms. Original research works and review articles covering the aforementioned or any novel biologics-mediated cancer treatment or immunotherapy will be considered for this Special Issue.

Guest Editor

Dr. Carlos Alberto Barrero

Proteomics and Metabolomics Facility, Moulder Center for Drug Discovery Research, Temple University, Philadelphia, PA 19140, USA

Deadline for manuscript submissions

25 September 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/276096

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)